Results 11 to 20 of about 6,578,993 (340)

Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma.

New England Journal of Medicine, 2023
BACKGROUND Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed CAR-T cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma.
J. San-Miguel, B. Dhakal, K. Yong, A. Spencer, S. Anguille, M. Mateos, C. Fernández de Larrea, J. Martínez-López, P. Moreau, C. Touzeau, X. Leleu, I. Avivi, M. Cavo, T. Ishida, S. Kim, W. Roeloffzen, N. V. D. van de Donk, D. Dytfeld, S. Sidana, L. Costa, A. Oriol, R. Popat, A. Khan, Y. Cohen, P. Ho, J. Griffin, N. Lendvai, C. Lonardi, A. Slaughter, J. Schecter, Carolyn C. Jackson, K. Connors, Katherine Li, E. Zudaire, Diana Chen, Jane Gilbert, T. Yeh, Sarah Nagle, E. Florendo, L. Pacaud, Nitin Patel, S. Harrison, H. Einsele   +42 more
semanticscholar   +1 more source

Serum Abnormal Metabolites for Evaluating Therapeutic Response and Prognosis of Patients With Multiple Myeloma

Frontiers in Oncology, 2022
AimsTo evaluate abnormal metabolites related to treatment response and prognosis of multiple myeloma (MM) patients through ultra performance liquid chromatography tandem mass spectrometry (UPLC-MS).MethodsForty-six symptomatic MM patients were included ...
Yujun Wei, Jinying Wang, Fei Chen, Xin Li, Jiajia Zhang, Man Shen, Ran Tang, Zhongxia Huang   +7 more
doaj   +1 more source

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

New England Journal of Medicine, 2023
BACKGROUND Daratumumab, a monoclonal antibody targeting CD38, has been approved for use with standard myeloma regimens. An evaluation of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone (VRd) for the treatment of ...
P. Sonneveld, M. Dimopoulos, M. Boccadoro, H. Quach, P. J. Ho, M. Beksaç, C. Hulin, Elisabetta Antonioli, X. Leleu, S. Mangiacavalli, A. Perrot, M. Cavo, A. Belotti, A. Broijl, F. Gay, R. Mina, I. Nijhof, Niels W C J van de Donk, E. Katodritou, Fredrik H. Schjesvold, Anna Sureda Balari, L. Rosiñol, Michel Delforge, W. Roeloffzen, T. Silzle, A. Vangsted, H. Einsele, A. Spencer, R. Hájek, Artur Jurczyszyn, Sarah Lonergan, T. Ahmadi, Yanfang Liu, Jianping Wang, D. Vieyra, E. M. van Brummelen, V. Vanquickelberghe, A. Sitthi-Amorn, Carla J. de Boer, R. Carson, P. Rodríguez-Otero, J. Bladé, P. Moreau   +42 more
semanticscholar   +1 more source

γ-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation

Blood Cancer Journal, 2022
We here defined the impacts of γ-secretase inhibitors (GSIs) on T-cell-dependent BCMA-specific multiple myeloma (MM) cell lysis and immunomodulatory effects induced by bispecific antibodies (BisAbs).
Hailin Chen, Tengteng Yu, Liang Lin, Lijie Xing, Shih-Feng Cho, Kenneth Wen, Kimberly Aardalen, Adwait Oka, Joni Lam, Mike Daley, Haihui Lu, Nikhil Munshi, Kenneth C. Anderson, Yu-Tzu Tai   +13 more
doaj   +1 more source

Epidemiology, Staging, and Management of Multiple Myeloma

Medical Science, 2021
Multiple myeloma (MM) is a plasma cell disorder that is on the rise throughout the world, especially in the US, Australia, and Western Europe. In the US, MM accounts for almost 2% of cancer diagnoses and over 2% of cancer deaths (more than double the ...
S. Padala, Adam Barsouk, Alexander Barsouk, Prashanth Rawla, Anusha Vakiti, R. Kolhe, V. Kota, Germame Ajebo   +7 more
semanticscholar   +1 more source

Extramedullary disease in multiple myeloma: a systematic literature review

Blood Cancer Journal, 2022
Extramedullary involvement (or extramedullary disease, EMD) represents an aggressive form of multiple myeloma (MM), characterized by the ability of a clone and/or subclone to thrive and grow independent of the bone marrow microenvironment.
J. Bladé, M. Beksaç, J. Caers, A. Jurczyszyn, M. von Lilienfeld-Toal, P. Moreau, L. Rasche, L. Rosiñol, S. Usmani, E. Zamagni, P. Richardson   +10 more
semanticscholar   +1 more source

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma

Nature Communications, 2021
BCMA targeting chimeric antigen receptor (CAR) T cell therapy has shown deep and durable responses in multiple myeloma. However, relapse following therapy is frequently observed, and mechanisms of resistance remain ill-defined.
M. Samur, M. Fulciniti, Anil Aktas Samur, A. Bazarbachi, Y. Tai, R. Prabhala, A. Alonso, A. Sperling, T. Campbell, F. Petrocca, K. Hege, S. Kaiser, H. A. Loiseau, K. Anderson, N. Munshi   +14 more
semanticscholar   +1 more source

Multiple Myeloma [PDF]

Hematology, 2002
AbstractThis update provides new insights into the biology, diagnosis, prognosis, and treatment of multiple myeloma (MM) and its complications.In Section I, Drs. John Shaughnessy, Jr., and Bart Barlogie first correlate global gene microarray expression profiling of patient MM samples with normal plasma cells to provide the basis for a developmental ...
Kenneth C, Anderson, John D, Shaughnessy, Bart, Barlogie, Jean-Luc, Harousseau, G David, Roodman   +4 more
openaire   +4 more sources

Multiple myeloma

Journal of the American Academy of Physician Assistants, 2015
This article presents a review of multiple myeloma, precursor states, and related plasma cell disorders. The clinical roles of fluorodeoxyglucose PET/computed tomography (CT) and the potential to improve the management of patients with multiple myeloma are discussed.
Christoph, Röllig, Stefan, Knop, Martin, Bornhäuser   +2 more
  +9 more sources

MRI in multiple myeloma : a pictorial review of diagnostic and post-treatment findings [PDF]

, 2016
Magnetic resonance imaging (MRI) is increasingly being used in the diagnostic work-up of patients with multiple myeloma. Since 2014, MRI findings are included in the new diagnostic criteria proposed by the International Myeloma Working Group.
A Baur, A Baur-Melnyk, A Stabler, AR Padhani, AR Padhani, AR Padhani, AR Padhani, B Turkbey, BC Vande Berg, C Hayes, C Jakob, C Lavini, C Lin, C Messiou, C Nanni, CM Zechmann, D Smith, DM Koh, E Mena, F Alyas, FE Lecouvet, G Pratt, GP Schmidt, HE Daldrup-Link, J Caers, J Hillengass, J Hillengass, J Hillengass, JC Dutoit, JC Dutoit, JC Dutoit, JR Silva Jr, KL Verstraete, KL Verstraete, LA Moulopoulos, LM Shah, M Fenchel, M Horger, M Merz, MA Dimopoulos, MM Khoo, P Bannas, R Garcia-Figueiras, RA Kyle, S Nosas-Garcia, SL Giles, SV Rajkumar, SV Rajkumar, T Derlin, T Derlin, TM Moehler, Y Zha   +51 more
core   +2 more sources